Dr. William M. Chamberlin

Dr. William M. Chamberlin is a retired physician. He received his undergraduate degree from Dartmouth College, his medical degree from Tufts University and completed his residency in Internal Medicine at William Beaumont Army Medical Center. From there, he completed a Fellowship in Gastroenterology at Walter Reed Army Medical Center. His early work experience took him to positions in Thailand, Southern Australia, Papua New Guinea, Germany and Japan. He served 20 years in the U.S. Army Medical Corps with his last assignment being at Walter Reed Army Institute of Research where he studied the immune systems responses to microbial infections. His primary research interests are non-tuberculosis mycobacteria in chronic inflammatory conditions, hormonal immune regulation, and emergence and evolution in biological systems. Since retirement he co-founded and is Chief Science Officer of Protibea Therapeutics, a company promoting immune therapy for infectious and inflammatory diseases.

His publications include:

1. W.M. Chamberlin. On Mycobacterium Avium Paratuberculosis and the Crohns Syndrome. El Paso Physician. Volume 22, number 10 October 1999. Ppg. 17-21.
2. Schwartz, Shafran, Romero, Piromelli, Biggerstaff, Chamberlin, Naser. Use of Short Term Culture for Identification of Mycobacterium avium paratuberculosis in tissue from Crohn’s Disease Patients.  European Society of Clinical Microbiology and Infectious Diseases, CMI, 6,303-307. 2000.
3. Chamberlin W, Hulten K, Graham DY, Antibiotics as Primary Therapy for Crohn’s Disease. Drugs of Today, October 2000, Prous Science, Barcelona.
4. Review Article: Mycobacterium avium subspecies paratuberculosis as One Cause of Crohn’ Disease. Chamberlin WM, Graham DY, Hulten K, El-Zamaity HMT, Schwartz MR, Naser SA, Shafran I, El-Zaatari   FAK.  Alimentary Pharmacology and Therapeutics 2001; 15: 337-346.
5. Chamberlin W, Naser S. Integrating theories of the etiology of Crohn’s Disease: On the etiology of Crohn’s Disease: Questioning the Hypotheses. Medical Science Monitor 2006; 12(2): RA27-33.
6. Chamberlin W, Naser S. Successful treatment of a Crohn’s Disease patient infected with bacteremic Mycobacterium paratuberculosis. Am J Gastroenterol. 2007 Mar;102(3):689-91.
7. Chamberlin W, Borody T, Naser S. MAP-associated Crohn’s disease MAP, Koch’s postulates, causality and Crohn’s disease. Dig Liver Dis. 2007 Aug;39(8):792-4. Epub 2007 Jul 3.
8. Chamberlin W. Importance of the Australian Crohn’s Disease Antibiotic Study. Gastroenterology 2007; Nov.
9. Chamberlin W, Naser S. Blood Cultures of 19 Crohn’s Disease Patients. Am J Gastroenterology 2008 Mar; 103(3) 802-3.
10. Chamberlin W, Shafran I. Anti-mycobacterials and Crohn’s Disease. Alimentary Pharmacology and Therapeutics. 2008 Aug 1:28(3):373-4.
11. Chamberlin William. Networks, Emergence, Iteration and Evolution. E:CO 2009 Nov.; pg 93-98.
12. Primary treatment of Crohn’s disease: combined antibiotics taking center stage. Chamberlin W, Borody TJ, Campbell J. Expert Rev Clin Immunol. 2011 Nov;7(6):751-60. doi: 10.1586/eci.11.43. Review.
13. Crohn’s disease and the mycobacterioses: a quarter century later. Causation or simple association? Chiodini RJ, Chamberlin WM, Sarosiek J, McCallum RW. Crit Rev Microbiol. 2012 Feb;38(1):52-93. doi: 10.3109/1040841X.2011.638273. Review
14. Much is still to be learned about pathogenic Mycobacteria. Chamberlin WM. J Crohns Colitis. 2012 Apr;6(3):390-1; author reply 392. doi: 10.1016/j.crohns.2011.12.011. Epub 2012 Jan
15. Mycobacterium avium ss paratuberculosis-associated diseases: piecing the Crohn’s puzzle together. Gitlin L, Borody TJ, Chamberlin W, Campbell J. J Clin Gastroenterol. 2012 Sep;46(8):649-55.
16. Crohn’s disease may be differentiated into 2 distinct biotypes based on the detection of bacterial genomic sequences and virulence genes within submucosal tissues. Chiodini RJ, Dowd SE, Davis B, Galandiuk S, Chamberlin WM, Kuenstner JT, McCallum RW, Zhang J. J Clin Gastroenterol. 2013 Aug;47(7):612-20.